<p>乔治亚州的一名联邦法官周一 reportedly 拒绝了 <strong>Teva Pharmaceutical Industries Ltd.</strong> (NYSE: TEVA) 延迟数千起诉讼中首场审判的请求，这些诉讼指控其 Paragard 宫内节育器 (IUD) 在移除时可能会断裂。</p>
<p>Paragard 是一种非激素的避孕装置，由铜制成，可以植入多年。</p>
<p>负责监督合并联邦诉讼的美国地区法官 <strong>Leigh Martin May</strong> 周一裁定，审判应按计划于 1 月 20 日进行。</p>
<p>该公司曾请求法院暂停案件，等待对早前拒绝 Teva 试图驳回诉讼的决定的上诉。</p>
<p>Teva 辩称，成功的上诉可能会完全结束诉讼，而该诉讼包括约 3800 起集中在联邦法院的诉讼。原告反驳称，该请求主要是拖延战术，会不必要地延缓案件的进展。</p>
<p>即将进行的审判将作为多区诉讼中的首个 “风向标” 审判，路透社报道。</p>
<p>在 11 月，Teva 和 <strong>The Cooper Companies</strong> (NASDAQ: COO) 在乔治亚州联邦法院寻求 简易判决，与 Paragard IUD 相关的多区诉讼的风向标审判，原告声称该装置可能在子宫内断裂，可能导致伤害、生育并发症和需要外科干预。</p>
<p>这些公司辩称，美国食品药品监督管理局 (FDA) 的批准优先于与该装置设计和警告标签相关的州法律索赔，声称原告提出的任何更改都与 FDA 批准的规格相冲突。</p>
<p>Teva 和 Cooper 认为，虽然在出现新信息时允许进行设计修改，但 Paragard 的断裂风险早已为人所知，并不符合该标准。他们坚持认为，所称缺陷并不证明在没有 FDA 授权的情况下进行单方面更改是合理的。</p>
<p>然而，美国地区法官 <strong>Leigh Martin May</strong> 对原告声称 Teva 花了五年时间才遵守 2010 年发布的 FDA 指令以更新 Paragard 警告标签表示担忧。May 法官指出，这一延迟似乎是故意的，并暗示 Teva 可能试图依赖自身的不合规来支持其优先权辩护。</p>
<p>Teva 开发了这种基于铜的装置，但在 2017 年将其出售给 Cooper Companies。May 法官之前允许原告 <strong>Pauline Rickard</strong>、<strong>Alisa Robere</strong> 和 <strong>Melody Braxton</strong> 的索赔进入风向标审判。</p>
<p>Cooper 在 2025 年 11 月单独辩称，应该将其从风向标审判中驳回，称其在原告收到装置后才收购 Paragard。</p>
<p>Teva 于 2017 年将 Paragard 产品出售给 CooperSurgical。对 CooperSurgical 在 Rickard 案件中的索赔被单独驳回。Teva 仍然是那些在公司拥有该产品期间收到该装置的患者的被告。</p>
<p>路透社指出，在 12 月的裁决中，May 法官驳回了 Teva 的论点，称联邦法律禁止这些索赔，因为公司在没有 FDA 批准的情况下无法更改 Paragard 的警告标签。</p>
<p>法官发现证据表明 Teva 收到了可能支持标签更新的新安全信息，无论患者何时收到该装置。</p>
<p><strong>价格动态</strong>：在周二的盘前交易中，TEVA 股票下跌 0.21%，报 32.72 美元。</p>
<p><em>图片来源：Shutterstock</em></p>

梯瓦制药

<p>一名联邦法官拒绝了梯瓦制药（Teva Pharmaceutical Industries）推迟与其 Paragard 宫内节育器相关的首次审判的请求，该审判定于 1 月 20 日开始。此次审判是涉及约 3,800 起诉讼的更大诉讼的一部分，这些诉讼指控该设备在移除时可能会断裂，导致受伤。梯瓦辩称，上诉可能会结束诉讼，但法官裁定审判应继续进行。关于梯瓦是否遵守 FDA 关于警告标签的要求也引发了担忧。梯瓦的股票在盘前交易中下跌 0.21%，报 32.72 美元</p>

<p>A Georgia federal judge on Monday reportedly denied <strong>Teva Pharmaceutical Industries Ltd.</strong> (NYSE: TEVA) a request to delay the first trial in thousands of lawsuits alleging its Paragard intrauterine device (IUD) can fracture during removal.</p>
<div class="lb-trans"><p>乔治亚州的一名联邦法官周一 reportedly 拒绝了 <strong>Teva Pharmaceutical Industries Ltd.</strong> (NYSE: TEVA) 延迟数千起诉讼中首场审判的请求，这些诉讼指控其 Paragard 宫内节育器 (IUD) 在移除时可能会断裂。</p>
</div><p>Paragard is a non-hormonal contraceptive device made of copper that can remain implanted for years.</p>
<div class="lb-trans"><p>Paragard 是一种非激素的避孕装置，由铜制成，可以植入多年。</p>
</div><p>U.S. District Judge <strong>Leigh Martin May</strong>, who is overseeing the consolidated federal litigation, ruled Monday that the trial should proceed as scheduled on January 20.</p>
<div class="lb-trans"><p>负责监督合并联邦诉讼的美国地区法官 <strong>Leigh Martin May</strong> 周一裁定，审判应按计划于 1 月 20 日进行。</p>
</div><p>The company had asked the court to pause the case while it appealed an earlier decision rejecting Teva's attempt to have the claims dismissed.</p>
<div class="lb-trans"><p>该公司曾请求法院暂停案件，等待对早前拒绝 Teva 试图驳回诉讼的决定的上诉。</p>
</div><p>Teva argued that a successful appeal could have ended the litigation entirely, which includes about 3,800 lawsuits centralized in federal court. Plaintiffs countered that the request was primarily a delay tactic and would unnecessarily stall progress in the case.</p>
<div class="lb-trans"><p>Teva 辩称，成功的上诉可能会完全结束诉讼，而该诉讼包括约 3800 起集中在联邦法院的诉讼。原告反驳称，该请求主要是拖延战术，会不必要地延缓案件的进展。</p>
</div><p>The upcoming trial will serve as the first &#34;bellwether&#34; in the multi-district litigation, Reuters reported.</p>
<div class="lb-trans"><p>即将进行的审判将作为多区诉讼中的首个 “风向标” 审判，路透社报道。</p>
</div><p>In November, Teva and <strong>The Cooper Companies</strong> (NASDAQ: COO) sought summary judgment ahead of bellwether trials in the Georgia federal court related to multidistrict litigation over the Paragard IUD, which plaintiffs allege can break inside the uterus, potentially causing injuries, fertility complications, and the need for surgical intervention.</p>
<div class="lb-trans"><p>在 11 月，Teva 和 <strong>The Cooper Companies</strong> (NASDAQ: COO) 在乔治亚州联邦法院寻求 简易判决，与 Paragard IUD 相关的多区诉讼的风向标审判，原告声称该装置可能在子宫内断裂，可能导致伤害、生育并发症和需要外科干预。</p>
</div><p>The companies argue that U.S. Food and Drug Administration (FDA) approval preempts state-law claims related to the device's design and warning labels, asserting that any changes proposed by plaintiffs would have conflicted with FDA-approved specifications.</p>
<div class="lb-trans"><p>这些公司辩称，美国食品药品监督管理局 (FDA) 的批准优先于与该装置设计和警告标签相关的州法律索赔，声称原告提出的任何更改都与 FDA 批准的规格相冲突。</p>
</div><p>Teva and Cooper contend that while design modifications are allowed when new information emerges, Paragard's risk of breakage has long been known and does not meet that threshold. They maintain that the alleged defects do not justify unilateral changes without FDA authorization.</p>
<div class="lb-trans"><p>Teva 和 Cooper 认为，虽然在出现新信息时允许进行设计修改，但 Paragard 的断裂风险早已为人所知，并不符合该标准。他们坚持认为，所称缺陷并不证明在没有 FDA 授权的情况下进行单方面更改是合理的。</p>
</div><p>U.S. District Judge <strong>Leigh Martin May</strong>, however, expressed concern over plaintiffs' claims that Teva took five years to comply with an FDA mandate issued in 2010 to update Paragard's warning labels. Judge May indicated the delay appeared intentional and suggested Teva may be attempting to rely on its own noncompliance to support its preemption defense.</p>
<div class="lb-trans"><p>然而，美国地区法官 <strong>Leigh Martin May</strong> 对原告声称 Teva 花了五年时间才遵守 2010 年发布的 FDA 指令以更新 Paragard 警告标签表示担忧。May 法官指出，这一延迟似乎是故意的，并暗示 Teva 可能试图依赖自身的不合规来支持其优先权辩护。</p>
</div><p>Teva developed the copper-based device but sold it to Cooper Companies in 2017. Judge May previously allowed claims from plaintiffs <strong>Pauline Rickard</strong>, <strong>Alisa Robere</strong>, and <strong>Melody Braxton</strong> to proceed to bellwether trials.</p>
<div class="lb-trans"><p>Teva 开发了这种基于铜的装置，但在 2017 年将其出售给 Cooper Companies。May 法官之前允许原告 <strong>Pauline Rickard</strong>、<strong>Alisa Robere</strong> 和 <strong>Melody Braxton</strong> 的索赔进入风向标审判。</p>
</div><p>Cooper, in November 2025, separately argues it should be dismissed from the bellwether trials, stating it acquired Paragard after the plaintiffs received their devices.</p>
<div class="lb-trans"><p>Cooper 在 2025 年 11 月单独辩称，应该将其从风向标审判中驳回，称其在原告收到装置后才收购 Paragard。</p>
</div><p>Teva sold the Paragard product to CooperSurgical in 2017. Claims against CooperSurgical in Rickard's case were dismissed separately. Teva remains a defendant for patients who received the device while the company owned the product.</p>
<div class="lb-trans"><p>Teva 于 2017 年将 Paragard 产品出售给 CooperSurgical。对 CooperSurgical 在 Rickard 案件中的索赔被单独驳回。Teva 仍然是那些在公司拥有该产品期间收到该装置的患者的被告。</p>
</div><p>Reuters noted that in a December ruling, May rejected Teva's argument that federal law barred the claims because the company could not change Paragard's warning label without FDA approval.</p>
<div class="lb-trans"><p>路透社指出，在 12 月的裁决中，May 法官驳回了 Teva 的论点，称联邦法律禁止这些索赔，因为公司在没有 FDA 批准的情况下无法更改 Paragard 的警告标签。</p>
</div><p>The judge found evidence suggesting Teva had received new safety information that could have supported a label update, regardless of when patients received the device.</p>
<div class="lb-trans"><p>法官发现证据表明 Teva 收到了可能支持标签更新的新安全信息，无论患者何时收到该装置。</p>
</div><p><strong>Price Action</strong>: TEVA stock is down 0.21% at $32.72 during the premarket session at the last check on Tuesday.</p>
<div class="lb-trans"><p><strong>价格动态</strong>：在周二的盘前交易中，TEVA 股票下跌 0.21%，报 32.72 美元。</p>
</div><p><em>Image: Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源：Shutterstock</em></p>
</div>

法官驳回了梯瓦制药暂停 Paragard 铜避孕设备诉讼审判的申请